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Summary
Background: Rhinitis is a major risk factor for asthma, so that evaluation of the
lower airways is recommended in patients with rhinitis. Exhaled nitric oxide (FENO) is
considered a marker of airway inflammation and it has been found to be useful for
the screening of patients with suspected diagnosis of asthma. Our aim was to assess
the validity and accuracy of FENO to identify patients with asthma in 48 non-smoking
patients with persistent rhinitis and asthma-like symptoms.
Methods: Asthma was diagnosed on the basis of 12% improvement in FEV1 after
salbutamol or a methocholine PD20FEV1o800 mg. Prior to lung function FENO was
measured with the single exhalation method at 50ml/s.
Results: The geometric mean (95% confidence interval) FENO was significantly higher
in the 18/48 asthmatics than in the non-asthmatic patients (60 ppb, CI 95%: 50–89,
versus 30 ppb, CI 95%: 28–45, P ¼ 0:001). Receiver operating characteristic (ROC)
curve for the diagnosis of asthma indicated that FENO is an acceptable discriminator
between patients with and without asthma (area under the ROC curve ¼ 0.78). None
of the asthmatic patients had FENO valueso25 ppb and all the patients with
FENO4100 ppb (n ¼ 5) were asthmatics. The sensitivity and specificity of FENO for
detecting asthma, using 36 ppb as cut-off point, were 78% and 60% and the positive
and negative predictive values were 54% and 82%, respectively.
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Conclusions: Measuring FENO may be useful for the screening of rhinitic patients
with asthma-like symptoms.
& 2006 Elsevier Ltd. All rights reserved.
Background
The relationship between rhinitis and asthma has
been extensively investigated, leading to the concept
of integration of the two conditions as manifestations
of one syndrome, the chronic allergic respiratory
syndrome.1 This syndrome has a wide spectrum of
severity. At the low end of this spectrum, the clinical
manifestations involve only the nose, which is rhinitis
without asthma; while at the high end of the
spectrum rhinitis and asthma coexist. Rhinitis is a
major risk factor for asthma2,3 and it is quite common
in patients with asthma, where rhinitis may be
present in up to 80% of patients.4 In patients with
rhinitis repetitive evaluation of the lower airways is
recommended as part of a clinical routine in order to
detect bronchial involvement.5 Exhaled nitric oxide
(FENO) has been proposed as a non-invasive marker of
airway inflammation in asthma.6–8 Measurement of
FENO has been found to be a useful diagnostic tool for
the screening of patients with a suspected diagnosis
of asthma,9 with a high degree of discriminating
power10,11 and greater diagnostic accuracy than
conventional tests.12 There are conflicting data
concerning FENO values measured in patients with
rhinitis. Increased levels have been reported in
subjects with allergic rhinitis compared with non-
allergic rhinitis.13 In addition, the same authors
reported similar FENO levels in subjects with allergic
rhinitis without asthma and subjects with allergic
asthma.14 On the other hand, Kharitonov et al.15 and,
more recently, Aronssson et al.16 found that, during
pollen season, patients with allergic rhinitis and
asthma had significantly higher FENO values compared
to those with rhinitis only, who had FENO values similar
to healthy controls. We wondered whether the
measurement of FENO could be useful, in a clinical
setting, for identifying those patients with rhinitis and
asthma-like symptoms, who will fulfil the diagnostic
criteria for asthma. We also wanted to determine a
cut-off value of the measurement of FENO for the
diagnosis of asthma in these particular patients.
Methods
Patients
We included 48 consecutive patients referred to our
Allergy Outpatients Clinic for diagnostic evaluation
of persistent rhinitis17 and lower airways symptoms
and 30 healthy controls. All patients had nasal
symptoms (sneezing, watery rhinorrea, nasal itch-
ing and nasal obstruction) for more than 4 days/
week and for more than 8 weeks and asthma-like
symptoms (cough, dyspnoea, chest tightness and
wheezing) during the last 2 months. In these
patients the diagnosis of asthma was further
investigated by means of a thorough clinical
assessment, spirometry, methacholine challenge
or bronchodilating tests. The exclusion criteria
were the use of steroids or any other anti-
inflammatory medications in the last 2 months,
current smoking (within previous 12 months),
previous diagnosis of asthma and respiratory infec-
tions during the last 6 weeks. Subjects did not
receive inhaled short-acting b2-mimetics in the 8 h
prior to the measurements. The study was ap-
proved by the local ethics committee and all
subjects gave their informed consent.
Study design
This was a prospective study investigating the value
of FENO for diagnosing asthma in patients with
persistent rhinitis and asthma-like symptoms. In
each patient FENO was measured prior to pulmonary
function tests and the diagnosis of asthma was
based on typical symptoms and on at least 12%
improvement in forced expiratory volume in 1 s
(FEV1) in response to salbutamol or methacholine
PD20 FEV1p800 mg in accordance with the current
international guidelines.18
Skin prick-testing was carried out in all the
patients with a panel of 14 inhalant allergens.
Atopy was defined as a wheal diameter 3mm or
greater in the presence of expected results in
control solutions (histamine dihydrochloride 10mg/
ml as a positive and solvent as a negative control).
Exhaled NO measurement
Measurements were obtained 2 h after breakfast,
immediately after mouthwash. Exhaled NO con-
centration (FENO) was measured using a chemilu-
minescence analyser (NiOX , Aerocrine AB, Solna,
Sweden) calibrated with a certified NO calibration
gas mixture. The online single exhalation technique
with exhalation rate 50ml/s and positive expira-
tory mouth pressure of 10 cm H2O was applied
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according to recommendations.19 The mean FENO of
three acceptable last 3 s end-expiratory plateau
measurements was calculated.
Statistics
Comparisons between continuous variables were
estimated with unpaired t-student’s test or Man-
n–Whitney test, depending on the distribution of
the variables. Categorical variables were compared
with the Fisher’s exact test. Two-by-two tables of
NO (low/high) versus asthma diagnosis (yes/no)
were prepared using the percentiles of the FENO
distribution as cut-off points. Pre-test probability
of disease, sensitivity, specificity, positive (PPV)
and negative (NPV) predictive values, and accuracy
were calculated for each of these tables.20 A
receiving operating characteristic curve (ROC) was
plotted in order to choose the best cut-off point.
Data were analysed with the statistical SPSS soft-
ware package (version 13.0 for Windows, Chicago,
IL, USA). All P-values were two tailed and
P-valueso0.05 were considered significant.
Results
On the basis of the significant response to bronch-
odilator (n ¼ 11, percentage of FEV1 improvement
above baseline after bronchodilating test was
17.472.14%) or airway hyperresponsiveness
(n ¼ 7, methacholine PD20FEV1 350798mcg) 18
out of 48 patients (37.5%) received the diagnosis of
asthma. The clinical and demographic character-
istics of patients with and without asthma are
shown in Table 1. There was no significant
difference in age, female/male ratio and atopy
between the two groups. Patients with asthma
reported higher prevalence of wheezing (100%
versus 73.3%, P ¼ 0:018) and lower FEV1
(90.074.1 versus 103.673.3% of predicted,
P ¼ 0:014) and FEV1/VC 100 (73.672.1 versus
83.871.05%, Po0:001) than patients without
asthma.
The geometric mean FENO was significantly higher
in patients with asthma than in the non-asthmatics
(59.7 ppb CI 95%: 50.2–89.0 versus 30.4 ppb CI 95%:
28.1–45.1, P ¼ 0:001) and both groups had FENO
significantly higher than healthy controls (12.2 ppb
CI 95%: 11.1–15.1, Po0:001 in both cases) (Fig. 1).
Table 2 lists different values of sensitivity,
specificity, positive and negative predictive values,
and accuracy for selected cut-off points of FENO
(from 10 to 100 ppb). The cut-off point of
FENO436 ppb was associated with the highest
combination of specificity (60.0%) and sensitivity
(77.8%), resulting in a negative predictive value
(NPV) of 81.8% and in a positive predictive value
(PPV) of 54%. Table 3 shows the distribution of the
patients according to FENO and diagnosis of asthma.
None of the asthmatic patients had FENOo25 ppb
(sensitivity for FENO425 ppb is 100% and
NPV ¼ 100%) and all the patients (n ¼ 5) with FENO
higher that 100 ppb were asthmatic. The ROC curve
for the measurement of FENO in the study popula-
tion is shown in Fig. 2. The area under the ROC
curve was 0.78.
Discussion
We have demonstrated that in patients with rhinitis
FENO values of patients with asthma were signifi-
cantly increased when compared to patients with
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Table 1 Clinical and demografical characteristics, symptoms, spirometric data and FENO in patients with and
without asthma.
Asthmatics Non-asthmatics P-value
Number of patients (%) 18 (37.5%) 30 (62.5%)
Mean age (yr) (range) 42.33 (17–69) 38.73 (11–75) 0.502
Male/female 9/9 12/18 0.558
Atopy, n (%) 14 (77.8%) 21 (70.0%) 0.74
FENO (ppb) 59.7 [50.2–89.0] 30.4 [28.1–45.1] 0.001
FEV1 (ml) 2755.3 [2327.9–3182.7] 3207.7 [2933.0–3482.4] 0.058
FEV1 (% predicted) 89.2 [80.1–98.4] 103.7 [96.9–110.4] 0.014
FEV1/FVC ratio (%) 72.9 [68.4–77.5] 83.8 [81.7–86.0] o0.001
Cough, n (%) 17 (94.4%) 27 (90.0%) 1.000
Chest tightness, n (%) 9 (50.0%) 13 (43.3%) 0.768
Dyspnaea, n (%) 14 (77.8%) 24 (80.0%) 1.000
Wheezing, n (%) 18 (100%) 22 (73.3%) 0.018
FEV1, FVC and FEV1/FVC are reported as means [95% CI], FENO is expressed as geometric mean [95% CI].
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similar symptoms of lower airways, who did not
fulfil the criteria for the diagnosis of asthma. The
prevalence of asthma we observed in our patients
(37.5%) is in complete agreement with data from
the literature. It has been estimated that up to 40%
of patients with allergic rhinitis have clinically
demonstrable asthma.21 Using ROC analysis we
have shown that the diagnostic power of FENO for
asthma is acceptable. The area under the curve
(AUC) was 0.78, comparable, for example, to that
of serum creatine kinase MB fraction measured at
6 h after the onset of chest pain to predict
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Table 2 Sensitivity, specificity, PPV, NPV and accuracy of FENO in the diagnosis of asthma in rhinitic patients.
Cut-off level of FENO Sensitivity Specificity PPV NPV Accuracy
410.00 1.000 0.033 38.30 100.00 39.58
415.00 1.000 0.133 40.00 100.00 43.75
420.00 1.000 0.333 46.15 100.00 56.25
425.00 1.000 0.467 52.94 100.00 66.67
430.00 0.778 0.500 51.61 88.23 64.58
434.00 0.778 0.533 48.27 78.95 60.42
436.00 0.778 0.600 53.84 81.81 66.67
440.00 0.611 0.633 47.83 72.00 60.42
445.00 0.611 0.733 57.89 75.86 68.75
450.00 0.556 0.767 61.11 76.67 70.83
455.00 0.500 0.800 56.25 71.87 66.67
460.00 0.500 0.867 69.23 73.53 70.83
465.00 0.444 0.867 66.67 72.22 70.83
475.00 0.444 0.900 66.67 72.22 70.83
480.00 0.389 0.967 88.89 74.36 77.08
485.00 0.278 0.967 85.71 70.73 72.92
4100.00 0.278 1.000 100.00 69.77 72.92
Figure 1 Exhaled nitric oxide (FENO) in rhinitic patients with and without asthma, and in healthy controls.
P ¼ 0:001 in
comparison with not asthmatic patients; #Po0:001 in comparison with health controls.
Table 3 Distribution of the patients according to
FENO and the diagnosis of asthma.
Cut-off level Asthma
Yes No
FENOo25 0 14
25oFENOo50 8 8
50oFENOo75 2 4
75oFENOo100 3 4
FENO4100 5 0
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myocardial infarction (AUC ¼ 0.78).22 The cut-off
point of FENO436 ppb was associated with the
highest combination of sensitivity (77.8%) and
specificity (60%). At lower cut-off level (i.e.
FENO425 ppb), the sensitivity of FENO was maximal,
although the specificity was low (47%). It is
interesting that, in this clinical setting, a negative
test (FENOo25 ppb) changes the pre-test probabil-
ity of asthma of 37.5% (18/48) to a post-test
probability of 0%, that is none of the 14 patients
with FENOo25 ppb was asthmatic. This latter
feature would make it a useful test in the clinical
setting to exclude asthma in patients with rhinitis
and symptoms suggestive of asthma, avoiding the
need of more demanding tests such as bronchial
challenge in nearly one third of patients (14/48).
This relatively low cut-off (25 ppb) was indeed
higher than the upper limit of the 95% CI in our
normal control subjects. This is due to the fact that
patients without asthma did have other conditions
that could also be associated with a small increase
in FENO. Actually, increased values of FENO have
been reported to be associated with rhinitis and
atopy,13,14 particularly when atopic subjects have
been exposed to the relevant allergen.23 On the
other hand, Kharitonov et al.15 and more recently
Aronsson et al.16 reported that patients with
rhinitis, during pollen season, had FENO similar to
the controls. In our study all patients with rhinitis,
most of them (21/30) were atopic, were selected if
they had asthma-like symptoms. It is possible that,
even in the absence of a diagnosis of asthma, these
patients had airway inflammation, which could
have contributed to the mild increase in FENO.
Sputum examination and/or comparison with a
group of patients with rhinitis without asthma-like
symptoms could have been of some help to clarify
this point. A higher cut-off point (e.g. FENO 55 ppb)
may increase the specificity at the cost of lower
sensitivity. Very high levels of FENO (4100 ppb)
were observed only in patients with asthma. By
using stepwise logistic regression analysis, Malm-
berg and colleagues24 found that clinical asthma
and airway eosinophilia were the most important
explanatory variables of high FENO. It is interesting
that we found two cases of eosinophilic bronchitis
(data not shown) among the 4 of the 12 patients
with FENO475 ppb, 8 of them were asthmatics. This
observation is clinically relevant, in that finding
high values of FENO, even when it is not associated
with the diagnosis of asthma, may be suggestive of
relevant clinical condition, such as eosinophilic
bronchitis. Moreover, according to a recent paper
of Smith and colleagues,25 high levels of FENO
measured in patients with hitherto undiagnosed
respiratory symptoms could predict steroid respon-
siveness, adding another clinical indication to mea-
suring FENO in patients with respiratory symptoms.
The predictive value of any test is dependent on
the gold standard used for the diagnosis. According
to GINA guidelines26 we defined asthma in our study
as the combination of respiratory symptoms, which
had to be present in all the patients, plus a positive
test for bronchial hyperresponsiveness and/or
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Figure 2 ROC curve for exhaled nitric oxide (FENO); data labels show the selected cut-off points of FENO levels.
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bronchodilator reversibility. Compared with adeno-
sine 50-monophosphate (AMP) methacholine ap-
pears to be less sensitive and less correlated with
FENO levels.
27,28 This will have resulted in a more
conservative outcome than if adenosine had been
used.
In conclusion, our data provide evidence of the
usefulness of FENO measurements in evaluating
patients with rhinitis and asthma-like symptoms.
When FENO values are below 25 ppb the likelihood
of asthma is virtually absent, and this simple non-
invasive measurement may obviate the need for a
challenge study. By contrast, high FENO value
increases the likelihood that asthma is present,
even if it may not be specific enough, unless for
very high values, to allow diagnosis without a
challenge study.
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